These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11569926)

  • 1. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
    Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
    Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
    Dori S; Vered M; David R; Buchner A
    J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression in salivary gland carcinomas: dependence on histological subtype.
    Glisson B; Colevas AD; Haddad R; Krane J; El-Naggar A; Kies M; Costello R; Summey C; Arquette M; Langer C; Amrein PC; Posner M
    Clin Cancer Res; 2004 Feb; 10(3):944-6. PubMed ID: 14871971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
    Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
    Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
    Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
    Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization].
    Skálová A; Stárek I; Vanĕcek T; Kucerová V; Plank L; Szépe P
    Cesk Patol; 2002; 38 Suppl 1():27-34. PubMed ID: 12677894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.
    Skálová A; Stárek I; Vanecek T; Kucerová V; Plank L; Szépe P; Di Palma S; Leivo I
    Histopathology; 2003 Apr; 42(4):348-56. PubMed ID: 12653946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
    Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
    Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
    Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
    Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
    Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
    Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.
    Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA
    Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
    Ryu HJ; Koh YW; Yoon SO
    Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.
    Press MF; Pike MC; Hung G; Zhou JY; Ma Y; George J; Dietz-Band J; James W; Slamon DJ; Batsakis JG
    Cancer Res; 1994 Nov; 54(21):5675-82. PubMed ID: 7522962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
    Simpson RH; Prasad AR; Lewis JE; Skálová A; David L
    Am J Surg Pathol; 2003 Aug; 27(8):1070-9. PubMed ID: 12883239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
    Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
    Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
    Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
    Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
    Johnson CJ; Barry MB; Vasef MA; Deyoung BR
    Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):54-8. PubMed ID: 18091319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
    Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.